科濟藥業-B(02171.HK):舒瑞基奧侖賽注射液研究結果的摘要已獲2025年ASCO年會接受進行口頭報吿
格隆匯3月31日丨科濟藥業-B(02171.HK)發佈公吿,舒瑞基奧侖賽注射液(產品編號:CT041,一款靶向Claudin18.2蛋白的自體CAR-T細胞治療候選產品)在中國開展的針對晚期胃癌╱食管胃結合部腺癌的確證性II期臨牀試驗(CT041-ST-01, NCT04581473)的研究結果摘要已被2025年美國臨牀腫瘤學會(ASCO)年會接受進行口頭報吿。摘要和進一步信息將於美國東部時間2025年5月22日後公佈。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.